Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QY201 Tablets in Non-Segmental Vitiligo
NCT07712523Phase 2Recruiting
- Sponsor
- E-nitiate
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of qy201 in nonsegmental vitiligo (NSV) (4 arms), sponsored by E-nitiate. Primary endpoint: Facial Vitiligo Area Scoring Index at 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
qy201
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT07712523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712523.